Polymerase gene mutation pattern in patients of chronic Hepatitis B treatment in Prof. Dr. W.Z. Johannes Hospital, Kupang, Indonesia

##plugins.themes.bootstrap3.article.sidebar##

PDF
DOI https://doi.org/10.13057/biodiv/d250115
Issue
Vol. 25 No. 1 (2024)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

##plugins.themes.bootstrap3.article.main##

AGUSTINA WELHELMINA DJUMA ♥
Department of Medical Laboratory Technology, Poltekkes Kemenkes Kupang. Jl. Piet A. Tallo-Liliba, Kupang 85361, East Nusa Tenggara, Indonesia
SHERLY DEWU
Prof. Dr. W.Z. Johannes Kupang Hospital. Jl. Moch Hatta No.19, Kupang 85111, East Nusa Tenggara, Indonesia
NORMA TIKU KAMBUNO
Department of Medical Laboratory Technology, Poltekkes Kemenkes Kupang. Jl. Piet A. Tallo-Liliba, Kupang 85361, East Nusa Tenggara, Indonesia
https://orcid.org/0000-0002-5085-3584
AYORINCE BANUNU
Department of Medical Laboratory Technology, Poltekkes Kemenkes Kupang. Jl. Piet A. Tallo-Liliba, Kupang 85361, East Nusa Tenggara, Indonesia
OTTO SAHAT MARTUA SILAEN
Doctoral Program in Biomedical Science, Faculty of Medicine, Universitas Indonesia. Jl. Salemba Raya No. 6, Central Jakarta 10430, Jakarta, Indonesia
https://orcid.org/0000-0002-5170-6797

Abstract

Abstract. Djuma AW, Dewu S, Kambuno NT, Banunu A, Silaen OSM. 2024. Polymerase gene mutation pattern in patients of chronic Hepatitis B treatment in Prof. Dr. W.Z. Johannes Hospital, Kupang, Indonesia. Biodiversitas 25: 150-155. Hepatitis B virus (HBV) infection is a significant global health concern, impacting over two billion people worldwide. Among them, more than 240 million individuals develop chronic HBV infection, placing them at a high risk of developing severe liver conditions such as cirrhosis, liver failure, and Hepatocellular Carcinoma (HCC). In 2013, Nusa Tenggara Timur (NTT) emerged as one of the Indonesian provinces with a high incidence of hepatitis cases. Long-term therapy has proven effective in halting disease progression but may also lead to the emergence of resistant mutations. This study aims to analyze mutation patterns in the Polymerase (P) gene as indicators of viral resistance to nucleotide analogs (NUCs) in HBV patients at RSUD Prof. Dr. W.Z. Johannes Kupang, a previously unreported case. The research was conducted at the Hematology-Oncology Medical Laboratory Division, Faculty of Medicine, Universitas Indonesia, RS. Dr. Cipto Mangunkusumo, Department of Internal Medicine, Jakarta. A total of 28 individual samples with positive Hepatitis B surface Antigen (HBsAg) were subjected to PCR sequencing, resulting in 23 positive samples. Mutation profiles were analyzed by comparing them with the reference sequence M54923. Sequencing of the Polymerase (P) gene region was successfully carried out for 14 samples. Among these, 12 (85.71%) exhibited nucleotide substitutions, while the remaining two (9.14%) did not show any mutations. The most prevalent substitution patterns in the P gene included rtQ228H, rtS127R, rtM135L, rtV243I, rtL257A, rtS127A, rtK323N, rtL326R, rtV214I, rtT312S, rtV281E, rtF290Y, rtM299I, rtQ306H, and rtK308N. No mutations associated with antiviral resistance were detected. The use of NUCs in chronic hepatitis B treatment is considered safe for patients at Prof. Dr. W.Z. Johannes Kupang Hospital.

##plugins.themes.bootstrap3.article.details##

References
Abdukadirova M, Khikmatullaeva A, Ibadullaeva N, Bakieva S. 2020. Molecular characterization of hepatitis b virus genotypes in Uzbekistan. Int J Infect Dis 101:511. DOI: 10.1016/J.IJID.2020.09.1327.
Balitbangkes, Badan Penelitian dan Pengembangan Kesehatan RI. 2007. Laporan Riset Kesehatan Dasar Nasional (Riskesdas). Depkes RI. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
Balitbangkes, Badan Penelitian dan Pengembangan Kesehatan RI. 2013. Laporan Riset Kesehatan Dasar Nasional (Riskesdas). Depkes RI. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
Bello KE, Mat Jusoh TNA, Irekeola AA, Abu N, Mohd Amin NAZ, Mustaffa N, Shueb RH. 2023. A recent prevalence of hepatitis b virus (hbv) genotypes and subtypes in asia: A systematic review and meta-analysis. Healthcare (Switzerland). MDPI. DOI: 10.3390/healthcare11071011.
Borgia G, Carleo MA, Gaeta GB, Gentile I. 2012. Hepatitis b in pregnancy. World J Gastroenterol 18 (34): 4677–4683. DOI: 10.3748/wjg.v18.i34.4677.
Ie SI, Turyadi, Sidarta E at al. 2015. High prevalence of hepatitis b virus infection in young adults in ternate, eastern indonesia. Am J Trop Med 93 (6): 1349–1355.
Kambuno NT, Sari A, Nurdin K, Novicadlitha Y, Siregar I. 2018. The relation of blood donors’ characteristic toward prevalences of hbsag and anti-hcv on blood transfussion unit of PMI in province of East Nusa Tenggara. In proceeding 1st. International Conference Health Polytechnic of Kupang, edited by Ferry Waangsir and Semy Kase, 303–310. Kupang, East Nusa Tenggara: Health Polytechnic of Kupang.
Kambuno NT, Bessie MF, Tangkelangi M, Djuma AW. 2019. Risk factors of intra-familial hepatitis b virus transmission among hepatitis b patients in Kupang, Indonesia. GMHC 7 (2): 151–156. DOI: 10.29313/gmhc.v7i2.4149.
Kambuno NT, Djuma AW, Barung EN, Siregar I. 2020. Risk factor for hepatitis b family transmission in Kupang Province of East Nusa Tenggara, Indonesia. PJMHS 14 (2): 1425–1428.
Kambuno NT, Octrysdey K, Nurdin KE, Novicadlitha Y, Barung EN, Fahmi Hafid F. 2021a. Sharing of personal sanitary kits as one risk factor of horizontal transmission of hepatitis b among children resident at Orphanage. Macedonian J Med Sci 9: 518-523. DOI: 10.3889/oamjms.2021.6406.
Kambuno NT, Waangsir F, Octrisdey, Tangkelangi M, Darwel, Ayatullah MI, Elengoe A. 2021b. Serology profile of hepatitis b in adolescents in Kupang, East Nusa Tenggara, Indonesia. Mal J Med Health Sci 17(SUPP4): 123-127.
Kang W, Ding Z, Shen L, Zhao Z, Huang G, Zhang J, Xiong Q, Zhang S, Zhang S, Wang F. 2014. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China. Vaccine 32 (27): 3362–3366. DOI: 10.1016/j.vaccine.2014.04.045.
Keikha M, Kamali H, Ghazvini K, Karbalaei M. 2022. Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections. Virus dis 33(4): 445-455. DOI: 10.1007/s13337-022-00790-y.
Kim H, Kim BJ. 2015. Association of pres/s mutations with occult hepatitis b virus (HBV) infection in south korea: transmission potential of distinct occult HBV variants. Int J Mol Sci 16 (6): 13595–13609. DOI: 10.3390/ijms160613595.
Kumar R. 2022. Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity. World J Hepatol 14(4): 708-718. DOI: 10.4254/wjh.v14.i4.708.
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. 2012. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6(3):531-61. DOI: 10.1007/s12072-012-9365-4.
Liu Y, Li X, Xin S, Xu Z, Chen R, Yang J, Liu L, Wong VW, Yang D, Chan HL, Xu D. 2015. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. J Viral Hepat 22(3): 328-34. DOI: 10.1111/jvh.12298.
Muljono DH. 2017. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian J Hepato-Gastroenterol 7 (1): 55–59. DOI: 10.5005%2Fjp-journals-l0018-1212.
Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. 2015. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 13(3):147-153. DOI: 10.1097/XEB.0000000000000054.
Nagahashi M, Matsuda Y, Moro K, Tsuchida J, Soma D, Hirose Y, Kobayashi T, Kosugi S, Takabe K, Komatsu M, Wakai T. 2016. DNA damage response and sphingolipid signaling in liver diseases. Surg Today 46(9):995-1005. DOI: 10.1007/s00595-015-1270-8.
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. 2020. Hepatitis B virus: Advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. American Society for Microbiology. DOI:10.1128/CMR.00046-19.
Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. 2021. Critical updates on chronic hepatitis B virus infection in 2021. Cureus 13(10): e19152. DOI: 10.7759/cureus.19152.
Pollicino T, Cacciola I, Saffioti F, Raimondo G. 2014. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 61(2): 408–417. DOI: 10.1016/j.jhep.2014.04.041.
Ranga A, Gupta A, Yadav L, Kumar S, Jain P. 2023. Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors. Eur J Med Chem 257: 115455. DOI: 10.1016/j.ejmech.2023.115455.
Reuter TQ, Gomes-Gouvea M, Chuffi S, Duque UH, Carvalho JA, Perini W, Queiroz MM, Segal IM, Azevedo RS, Pinho JRR. 2022. Hepatitis B virus genotypes and subgenotypes and the natural history and epidemiology of hepatitis B. Ann Hepatol 27 Suppl (1):100574. DOI: 10.1016/j.aohep.2021.100574.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. 2016. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10(1):1-98. DOI: 10.1007/s12072-015-9675-4.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. 2015. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350: g7647. DOI: 10.1136/bmj.g7647.
Shedain PR, Devkota MD, Banjara MR Ling H, Dhital S. 2017. Prevalence and risk factors of hepatitis b infection among mothers and children with hepatitis b infected mother in upper Dolpa, Nepal. BMC Infect Dis 17: 667. DOI: 10.1186/s12879-017-2763-4.
Silaen OSM, Murtini S, Pamungkas J, Nugroho CMH. 2020. Isolation and molecular characterization of fowl aviadenovirus associated with inclusion body hepatitis from poultry in Banten and West Java, Indonesia. Vet World 13(9):1940-1946. DOI: 10.14202/vetworld.2020.1940-1946.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. 2016. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1):261-283. DOI: 10.1002/hep.28156.
Thedja MD, Muljono DH, Nurainy N, Sukowati CH, Verhoef J, Marzuki S. 2011. Ethnogeographical structure of hepatitis B virus genotype distribution in Indonesia and discovery of a new subgenotype, B9. Arch Virol (5): 855-868. DOI: 10.1007/s00705-011-0926-y.
Turyadi, Thedja MD, Ie SI, Narita V, Nurainy N, Muljono DH. 2018. Karakteristik reverse transcriptase gen polymerase virus hepatitis b pada penderita hepatitis b kronis asimptomatik pra-pengobatan. eJKI 5 (3): 183-190. DOI: 10.23886/ejki.5.8046.183-90.
Wibowo BP, Susanto E, Supriono, Mustika S. 2020. Perbandingan potensi telbivudin dan tenofovir dalam menurunkan skor aspartate transaminase to platelet ratio index (APRI) pada pasien hepatitis b. Majalah Kesehatan 7(1): 41-47.
Wijayadi T, Sjahril R, Turyadi, Ie SI, Wahyuni R, Pattelongi I, Massi MN, Yusuf I, Muljono DH. 2018. Seroepidemiology of HBV infection among health-care workers in South Sulawesi, Indonesia. BMC Infect Dis 18(1): 279. DOI: 10.1186/s12879-018-3190-x.
Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N. 2015. Hepatitis B virus burden in developing countries. World J Gastroenterol 21(42): 11941-11953. DOI: 10.3748/wjg.v21.i42.11941.
Zhang QF, Shao JY, Yin WW, Xia Y, Chen L, Wang X, Hu HD, Hu P, Ren H, Zhang DZ. 2016. Altered immune profiles of natural killer cells in chronic hepatitis b patients: a systematic review and meta-analysis. PLoS One 11(8): e0160171. DOI: 10.1371/journal.pone.0160171.
Zheng X, Wang J, Yang D. 2015. Antiviral therapy for chronic hepatitis b in China. Med Microbiol Immunol 204 (1): 115–120. DOI: 10.1007/s00430-014-0380-z.
Zoulim F, Unit I, Thomas CA. 2004. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis b virus infection. Antiviral Res 64: 1–15. DOI: 10.1016/j.antiviral.2004.07.003.

Most read articles by the same author(s)